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Abstract
Purpose Lower gastrointestinal bleeding (LGIB) is common and risk stratification scores can guide clinical decision-making.
There is no robust risk stratification tool specific for LGIB, with existing tools not routinely adopted. We aimed to develop and
validate a risk stratification tool for LGIB.
Methods Retrospective review of LGIB admissions to three centres between 2010 and 2018 formed the derivation cohort. Using
regressional analysis within a machine learning technique, risk factors for adverse outcomes were identified, forming a simple
risk stratification score—The Birmingham Score. Retrospective review of an additional centre, not included in the derivation
cohort, was performed to validate the score.
Results Data from 469 patients were included in the derivation cohort and 180 in the validation cohort. Admission haemoglobin
OR 1.07(95% CI 1.06–1.08) and male gender OR 2.29(95% CI 1.40–3.77) predicted adverse outcomes in the derivation cohort
AUC 0.86(95% CI 0.82–0.90) which outperformed the Blatchford 0.81(95% CI 0.77–0.85), Rockall 0.60(95% CI 0.55–0.65)
and AIM65 0.55(0.50–0.60) scores and in the validation cohort AUC 0.80(95% CI 0.73–0.87) which outperformed the
Blatchford 0.77(95% CI 0.70–0.85), Rockall 0.67(95% CI 0.59–0.75) and AIM 65 scores 0.61(95% CI 0.53–0.69). The
Birmingham Score also performs well at predicting adverse outcomes from diverticular bleeding AUC 0.87 (95% CI 0.75–
0.98). A score of 7 predicts a 94% probability of adverse outcome.
Conclusion The Birmingham Score represents a simple risk stratification score that can be used promptly on patients admitted
with LGIB.
Keywords Lower gastrointestinal bleeding . Risk stratification . Risk factors . Triaging tool
Introduction
Lower gastrointestinal bleeding (LGIB) has an incidence of
approximately 33 per 100,000 population and a frequency
approaching that of upper gastrointestinal causes [1].
Common causes include diverticular disease, haemorrhoids,
colitis and colorectal cancer/polyps [2–4]. LGIB can range
from benign to potentially life threatening, with the majority
of cases resolving spontaneously [2].
Evaluation with a risk stratification score may be useful in
aiding clinical decision-making. There are few validated risk
stratification scoring systems designed specifically for LGIB
[5], unlike upper gastrointestinal bleeding, for which there are
well-validated and robust predictive scoring models [6–8].
The current scoring systems specific for LGIB [9–11] have
limitations including requirement for inpatient colonoscopy
and prolonged patient observation, meaning patients require
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admission and the scores cannot be used as an emergency
triage tool [9, 11–13]. Therefore, they are not widely used in
clinical practice [14]. More recently, Oakland and colleagues
developed and validated a LGIB score predicting suitability
for safe early discharge [15]. The criteria for safe discharge
were the absence of certain interventions such as blood trans-
fusion, which may not truly reflect severity of cases [15]. It
also requires the knowledge of previous admissions with
LGIB, which is information that may not consistently be
available to admitting clinicians.
Developing a robust and reproducible scoring system would
allow clinicians to potentially facilitate early discharge for low
risk patients and identify high-risk patients, who may require
more intensive management such as close monitoring or critical
care. The aim of this study was to identify risk factors for
adverse outcomes from LGIB and subsequently develop and
validate a risk stratification tool that would allow early decision
making at the point of admission without the need for
prolonged observation and before adverse outcomes such as
blood transfusion or haemostatic intervention have taken place.
Patients and methods
Setting and participants
We conducted a multicentre retrospective review of all admis-
sions with LGIB (age ≥ 16 years) presenting to University
Hospital Birmingham NHS Trust (UHB), University Hospital
Coventry and Warwickshire (UHCW), Sandwell and West
Birmingham NHS Trust (SWBH) and the Royal
Wolverhampton NHS Trust (RWH) between 2010 and 2018.
We used ICD coding to identify acute admissions with
haematochezia and rectal bleeding. Retrospective electronic
medical records were reviewed to confirm LGIB at the point
of admission; therefore, it was not possible to gather data on the
number of patients undergoing upper GI endoscopy for exclu-
sion of upper GI bleeding. Patients attending for outpatient
appointments for LGIB and patients attending the emergency
department and subsequently discharged without admission
were excluded. Case notes were reviewed to collect demo-
graphic data, co-morbidities (grouped as per Glasgow-
Blatchford score [7]), admission laboratory testing, admission
vital signs, presence of syncope and altered mental status.
Altered mental status was recorded if confusion, disorientation
or reduced conscious level was noted on admission hospital
records, which is recorded as a standard of practice. Adverse
outcomes collected included blood transfusion, endoscopic in-
tervention (APC, injection therapy, clips), CT angiography
(positive or negative), surgical intervention, re-bleeding (re-
admission within 30 days) and mortality. Sub-group analysis
was performed on those patients with a proven endoscopic
diagnosis of LGIB secondary to diverticular disease.
Outcomes and endpoints
The primary outcome of the study was adverse outcomes. The
adverse outcomes of blood transfusion, endoscopic interven-
tion, CT angiography, surgical intervention, re-bleeding and
mortality were pooled to allow statistical analysis given the
low incidence of mortality from LGIB (3.4%) [3]. These out-
comes were selected as they reflect a requirement for an inpa-
tient admission.
Statistical analysis
Risk score derivation
For the derivation cohort, data fromUHB, UHCWand SWBH
were analysed, using regressional analysis within a machine
learning technique (namely R-package CARRoT-Bazarova
and Raseta https://CRAN.R-project.org/package=CARRoT,
2018), which has been previously used for prediction in
clinical set-ups [16] (25, 26) and combines principles of good
practice from machine learning such as cross-validation [17]
and subset regression [18] restricted by the rule of ten events
per variable (‘one in ten rule’) [19]. The latter means that only
the regression models where the number of variables multi-
plied by ten does not exceed the number of patients in the less
likely category of the training set (adverse outcomes).
Therefore, regression models consisting of all possible com-
binations of factors satisfying this condition were used to pre-
dict adverse outcomes. The variables considered were gender,
age, co-morbidities, admission haemoglobin, albumin, INR,
urea, blood pressure, heart rate, melena, syncope and altered
mental state. Within the package CARRoT, the number of
cross-validations [17] was set to 1000. For each cross-valida-
tion, the dataset was randomly partitioned into the training set
(90% of the data) and the test set (10% of the data), and the
corresponding regression models were fit to the training set
and their predictive power was assessed on the test set. Given
159 patients experienced adverse outcomes, according to the
‘rule of 10’ on average of up to 14 variables could be included
in the model during each cross-validation (around 16,000
models). The best models were identified via maximizing av-
erage AUROCs computed over all cross-validations on the
test sets. Then, the best model fitted to the whole dataset and
the corresponding ORs were computed. The factors with 95%
CI for ORs containing value 1 were excluded from the set of
variables. Then, machine-learning algorithm was applied to
the modified set of variables. This procedure was repeated
until the final model consisted of factors with ORs not con-
taining 1 when fitted to the whole dataset. The score was
developed by fitting the corresponding regression to the whole
dataset; the coefficients of the regression were rounded. Then,
the curve was produced and its most efficient breakpoints
determined by Youden’s J-statistic [20] were used to create
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an integer valued discrete score. The AUROC corresponding
to the newly developed score were calculated using a boot-
strapping method to assess the predictive power of the score
available through an R-package pROC [21].
Risk score validation
Validation of The Birmingham Score took place by using the
risk algorithm on the dataset from RWH. Estimates of the area
under the receiver operating curve (AUROC) were calculated
by applying the score directly to the whole dataset and its
confidence intervals were obtained by using a bootstrapping
method repeated 2000 times for this dataset against The
Birmingham Score using R-package pROC.
For comparisons of the derivation and validation groups,
we used independent t-test statistics in order to compare
means of the continuous variables (Table 1). For categorical
outcomes, we used chi-squared and Fisher’s exact test.
Analysis was performed using statistical software R (R Core
Team 2017). A p value of < 0.05 was considered to be statis-
tically significant.
Ethics
Formal local audit approval was obtained at each participating
centre (CARMS-13587).
Results
Derivation cohort
Patient characteristics
A total of 473 patients were identified in the derivation cohort,
4 were removed due to a lack of clinical data (Table 1).
Risk score derivation
Logistic regression modelling demonstrated the performance
of each variable in predicting adverse outcomes (Table 2). The
output of R-package CARRoTwas a model consisting of four
variables, gender OR 2.31 (95% CI 1.40–3.82), admission
Haemoglobin OR 1.07 (95% CI 1.05–1.08), admission urea
OR 1.03 (95% CI 0.97–1.09) and syncope OR 0.56 (95% CI
0.23–1.39) demonstrating an average AUROC over all cross-
validations of 0.86. Having observed that 95% CI for syncope
contains the value 1 and suggests that absence of syncope is
associated with adverse outcomes, we excluded syncope from
the set of variables and re-ran the analysis on the modified set
of variables. The best-selected model consisted of three vari-
ables: gender, admission haemoglobin and admission urea.
We excluded urea from the set of variables given that its
95% CI for OR contained 1 and repeated the procedure again.
The final output was admission haemoglobin OR 1.07 (95%
Table 1 Patient characteristics of the derivation and validation groups
Derivation cohort
(n = 469)
Validation cohort
(n = 180)
P value Diverticular
cohort (n = 57)
P value
Median age (range) 71 (16–98) 71 (19–100) 0.876 77 (29–97) 0.0003
Age ≥ 80 years 147 (31.3%) 59 (32.8%) 0.797 21 (36.8%) 0.49
Co-morbidities (cardiac failure, ischaemic heart disease,
major co-morbidity, renal/liver failure, metastatic cancer)
230 (49.3%) 92 (51.1%) 0.701 21 (36.8%) 0.110
Median admission Haemoglobin (range) 120 g/L (29–181) 121 g/L (54–171) 0.157 114 g/L (52–162) 0.472
Haemoglobin ≤ 100 g/L 139 (29.6%) 47 (26.1%) 0.428 20 (35.1%) 0.323
Median admission systolic BP (range) 132 mmHg (85–218) 130 mmHg (66–218) 0.887 135 mmHg (95–210) 0.323
Admission systolic BP ≤ 90 mmHg 6 (1.3%) 1 (0.56%) 0.680 0 (0.0%)
Mean admission heart rate (range) 82 bpm (48–131) 86 bpm (30–240) 0.005 81 bpm (60–114) 0.853
Admission heart rate ≥ 100 bpm 51 (11%) 41 (22.8%) ≤ 0.001 4 (7.0%) 0.503
Adverse outcomes
Blood transfusion 118 (25.2%) 45 (25.0%) 1.0 18 (31.6%) 0.376
Endoscopic intervention 24 (5.1%) 4 (2.3%) 0.162 1 (1.8%)
CT angiography 38 (8.1%) 0 (0.0%) 2 (3.5%)
Surgery 11 (2.3%) 6 (3.3%) 0.583 0 (0.0%)
Re-bleeding 29 (6.2%) 17 (9.4%) 0.201 3 (5.2%)
Mortality in-hospital 10 (2.1%) 8 (4.4%) 0.115 0 (0.0%)
Mortality < 30 days 15 (3.2%) 6 (3.3%) 1.0 0 (0.0%)
Mean length of hospital stay (range) 5.8 days (1–107) 7.1 (1–87) 0.179 6.5 (0–35) 0.486
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CI 01.06–1.08) and gender OR 2.29 (95% CI 1.4–3.77) dem-
onstrating an average AUROC over all cross-validations of
0.86—The Birmingham Score. The corresponding AUROC
was 0.86 (95% CI 0.82–0.90) for this score.
Comparison with other gastrointestinal bleeding scores
The Birmingham Score outperforms the GBS 0.81 (95% CI
0.77–0.85), modified Oakland score 0.84 (95% CI 0.80–
0.88), Rockall 0.60 (95% CI 0.55–0.65) and AIM65 0.55
(0.50–0.60) (Fig. 1). Note that for Oakland score, we did not
take into account previous history of re-bleeding and DRE
findings, as the information was not collected in this study.
The cut-offs for The Birmingham Score are shown in Table 3.
Using The Birmingham Score, the probabilities of a patient
experiencing an adverse outcome were calculated (Table 4).
Validation Cohort
Patient characteristics
In the validation cohort, a total of 203 patients were identified;
however, 23 were removed due to a lack of clinical data
(Table 1). There was a statistically significant difference be-
tween the derivation vs. validation groups in the mean admis-
sion heart rate (82 vs. 87 p = 0.032) and number of patients
admitted with a heart rate ≥ 100 (11% vs. 22.7% p = 0.001).
Risk score validation and comparison with other
gastrointestinal bleeding scores
Using the validation dataset, the risk stratification scores were
applied. The Birmingham Score AUROC 0.80 (95% CI 0.73–
0.87) outperformed the GBS AUROC 0.77 (95% CI 0.70–
0.85), modified Oakland Score 0.77 (95% CI 0.70–0.85),
Rockall Score AUROC 0.67 (95% CI 0.59–0.75) and AIM
65 score AUROC 0.61 (95% CI 0.53–0.69) (Fig. 2).
The distribution of scores and proportion of patients having
an adverse outcome in the combined cohort (derivation and
validation) are shown in Fig. 3. Overall, 145 patients (22.3%)
were admittedwith a Birmingham Score of < 2 with 10 (6.9%)
noted to have an adverse outcome. A total of 201 (31.0%)
patients scored ≥ 5 and 148 of those had an adverse outcome
(73.6%). An example of how The Birmingham Score might
be used in clinical practice is shown in Fig. 4.
Prediction of adverse outcomes associated
with diverticular bleeding
A total of 57 patients (8.7%) had an endoscopic diagnosis of
LGIB secondary to diverticular disease. There was a signifi-
cant difference between this cohort and the derivation cohort
in terms of age, with the diverticular group have a higher
median age of 77 (range29–97) vs. 71 (range 16–98)
p0.0003. The Birmingham Score predicted adverse outcomes
in this cohort of patients with an AUROC 0.87 (95% CI 0.75–
0.98), Blatchford Score 0.83 (0.71–0.95), modified Oakland
score 0.81 (0.67–0.96), AIM65 0.55 (0.50–0.68) and Rockall
score 0.50 (0.50–0.67).
Discussion
We have developed and validated a triaging tool that can guide
decision-making on hospitalization, by using a multicentre
database, which outperforms validated upper GI bleeding
scores including Glasgow Blatchford Score, Rockall and
AIM65. The risk factors included are admission haemoglobin
and male gender. A Birmingham score of 6–7 points equates
to a probability of an adverse outcome of 90% and a score of
< 2 gives a probability of an adverse outcome of 4%.
The strength of The Birmingham Score is that it was de-
veloped from a large database from multiple acute care hos-
pitals. These centres include academic centres (UHB and
UHCW) as well as community centres (SWBH and RWH)
making the results more generalizable. As individual case
notes were reviewed, accurate data on adverse outcomes was
collated, which may not have been possible from administra-
tive databases or population statistics that had been used in
other LGIB studies. The score can be used at the point of
admission with one single blood test allowing prompt deci-
sions and is more simple than other scores including the
Oakland score but predicts adverse outcome in a similar
manner.
Risk stratification tools are integral part of the management
of upper gastrointestinal bleeding [6–8], which allows prompt
recognition of high-risk patients requiring intensive treatment
Table 2 Univariate analysis of variables collected
Variable OR OR 95% CI P value
Gender 1.63 (1.11, 2.4) 0.01
Age 1.01 (1.0, 1.02) 0.02
Co-morbidities (cardiac
failure, ischaemic heart
disease, major co-morbidity,
renal/liver failure,
metastatic cancer)
1.28 (1.09, 1.52) 0.003
Haemoglobin 1.07 (1.05–1.07) < 2 × 10^(−16)
Urea 1.12 (1.07, 1.18) 3.3 × 10^(−6)
Albumin 3.78 (1.83, 8.13) 0.00041
INR 1.97 (1.15, 3.34) 0.01
BP 0.98 (0.97, 0.99) 5.29 × 10^(−5)
HR 1.01 (0.99, 1.02) 0.22
Syncope 0.99 (0.51, 1.77) 0.97
Altered mental state 4.71 (1.29, 22.09) 0.03
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and low risk patients facilitating early discharge. In LGIB,
existing stratification tools are not widely used clinically
[14]. One potential difficulty in developing a LGIB risk strat-
ification score is the heterogeneous nature of LGIB. There is a
wide range of aetiologies including diverticular disease, coli-
tis, malignancy and haemorrhoids [3] and as a result acuity
and prognosis will vary. Tapaskar et al. (n = 170 patients) in a
single-centre retrospective study demonstrated no single risk
stratification score has the best predictive ability to predict
adverse outcomes [22]. Limitations of previous studies in-
clude inclusion criteria of patients having a colonoscopy on
the index admission [13], require prolonged observation of
patients reducing its use as a triaging tool [9, 11, 12] and poor
performance at differentiating low and high-risk patients [10,
23].
More recently, attempts have beenmade to identify patients
who are at low-risk and not requiring in-hospital intervention.
Hreinsson et al. (n = 581 patients) developed the SHA2PE
score which predicts low-risk patients not requiring in-
hospital intervention with an AUC of 0.83 and NPV of 96%
[24]. This study was limited by its retrospective, single-centre
design, including patients discharged from ER and only in-
cluding patients who had an endoscopy. Oakland et al. (exter-
nal validation n = 288) also identified risk factors associated
with a low likelihood of adverse outcome, with a score of < 8
predicting a 95% probability of safe discharge [15]. Similar to
the present study, the Oakland score excluded patients already
admitted to hospital, and included blood transfusion, thera-
peutic intervention to control bleeding, in-hospital mortality,
surgical intervention and re-admission within 28 days as ad-
verse outcomes, the absence of which reflected safe discharge
after presentation [15]. The most common adverse outcome in
the Oakland study was blood transfusion (25%) which is sim-
ilar to the present study. This score is heavily weighted by
admission haemoglobin (up to 22 points from a total of 35),
similar to The Birmingham Score.
The Birmingham Score represents a simple risk strati-
fication score, which is objective and does not require
observation of patients nor endoscopic information.
Therefore, it can be useful clinically for timely decision-
making at the time of presentation, although as with all
Fig. 1 ROC curves for the
derivation dataset. (a)
Birmingham Score AUROC 0.86
(95% CI 0.82–0.90), (b) GBS
AUROC 0.81 (95% CI 0.77–
0.85), (c) modified Oakland score
Rockall score AUROC0.84 (95%
CI 0.80–0.88), (d) Rockall score
AUROC 0.60 (95% CI 0.55–
0.65), and (e) AIM65 AUROC
0.55 (95% CI 0.50–0.60)
Table 3 The
Birmingham Score Variable Points
Male gender 1
Admission haemoglobin
< 83 6 points
83- < 97 5 points
97- < 112 4 points
112- < 116 3 points
116- < 133 2 points
133- < 147 1 points
>147 0 points
Table 4 Probabilities of
experiencing adverse outcomes
using The Birmingham Score
Birmingham
score (points)
Probability %
(95% CI)
6–7 90 (82–95)
4–5 38 (30–47)
2–3 18 (13–24)
< 2 4 (1–11)
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risk predictive scores, it has to be used in clinical context
and clearly if there are significant co-morbidities or frailty
for example then a clinical decision has to be made at the
individual patient level. Surprisingly, factors such as age
and co-morbidities did not predict adverse outcomes from
LGIB; however, this is consistent with the Oakland Score
[15] which does not feature co-morbidities in its risk
model and age has a maximum weighting of 2 points
(out of 35).
The adverse outcomes chosen were those that reflect a
requirement for inpatient management and were pooled to-
gether in order to power a meaningful risk stratification score
and since themost common adverse outcomewas blood trans-
fusion, The Birmingham Score is therefore heavily weighted
Fig. 2 ROC curves for the
validation dataset. (a)
Birmingham score AUROC 0.80
(95% CI 0.73–0.87), (b) GBS
AUROC 0.77 (95% CI 0.70–
0.85), (c) modified Oakland score
AUROC 0.77 (95% CI 0.70–
0.85), (d) Rockall score AUROC
0.67 (95% CI 0.59–0.75), and (e)
AIM65 AUROC 0.61 (95% CI
0.53–0.69)
135
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Fig. 3 Distribution of Birmingham scores and proportion of patients with adverse outcomes
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by admission haemoglobin. Tapaskar et al. also demonstrated
the importance of admission haemoglobin in predicting severe
bleeding (OR 1.28 (1.10–1.49)) [22]. This is similar to the
Oakland Score [15]; however, The Birmingham Score is sim-
pler with less variables required and does not require knowl-
edge of previous LGIB admissions, which may not be imme-
diately available to admitting clinicians. Male gender was
found to increase risk of an adverse outcome, which is con-
sistent with the Oakland score [9, 15]. When comparing val-
idated upper GI bleeding scores, we found that the Glasgow
Blatchford Score outperforms the Rockall and AIM65 scores,
which is also consistent with another study [15]. We made
comparisons with upper GI bleeding scores as within the
UK, these scores are in common use and therefore the data
available reflects this. The Birmingham Score performed well
in predicting adverse outcomes from diverticular disease
(AUROC 0.87 (95% CI 0.75–0.98)), which given this is most
common cause of LGIB means The Birmingham Score is
likely to be more widely applicable in clinical practice [3].
Using The Birmingham Score, 22.3% of patients had a low
probability of an adverse outcome (Birmingham Score < 2)
and therefore could be considered for early discharge, poten-
tially allowing significant healthcare savings.
One of the strengths of the present study is the size of the
derivation cohort used (n = 469), which is more than other
LGIB studies [9–11, 13, 22]. The machine learning technique
is a strength to the present study as it allows internal validation
at the stage of training which is achieved by multiple cross-
validations within the derivation cohort. This way, the best
predictive variables are selected for the final score which in
turn leads to the highest predictive power measured via
AUROC. Variable selection based on internal cross-
validations also yields a score which is more likely to stay
robust upon external validation, which we demonstrate on
the validation cohort. Internal and external validations are
important components in predictive clinical research as they
guarantee the best predictive power, robustness of the selected
model and allow to avoid overfitting [25]. The Birmingham
Score performs favourably to the Oakland score, however is
less complex with fewer components.
There are limitations to this study. The retrospective nature
of the study mean the conclusions cannot be generalized until
prospective validation takes place. The patients included were
those whom were admitted with LGIB excluding patients at-
tending to emergency departments and subsequently
discharged. However, this study suggests that low-risk pa-
tients are admitted without clear criteria to use in triage.
There is bias towards more significant LGIB necessitating
admission, given patients presenting to emergency depart-
ments and subsequently discharged were not included.
Together with this, the inclusion of severe presentations of
patients unfit for inpatient colonoscopy means there is an el-
ement of selection bias. The centres included covers a wide
geographical area; however, it was not possible to establish
whether individual patients re-presented at other hospitals in
the region, which means some episodes of re-admission may
not have been captured. The patients included are those whose
primary reason for admission was LGIB; therefore, The
Birmingham Score cannot be applied to patients having a
LGIB during an inpatient stay for other reasons or those pa-
tients presenting with multiple presenting complaints in addi-
tion to LGIB. The majority of adverse outcomes included in
this study could be described as soft outcomes (blood transfu-
sion, endoscopic intervention, CT angiography) as practice
may vary between hospitals. Given hard outcomes such as
mortality is low in LGIB, a large multicentre study would be
needed to give sufficient sample size to power the study. This
is a similar limitation in other LGIB studies [15].
In summary, The Birmingham Score represents a simple
risk stratification tool that is easily calculated at the point of
Presentaon with LGIB
Inial assessment and 
invesgaons
Birmingham Score
2-5<2 6-7
Consider early discharge 
with outpaent 
invesgaons
Admit with 
observaon
Admit and consider high 
dependency care/intensive 
monitoring 
Fig. 4 Flowchart of The
Birmingham Score in use in the
Emergency Department
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admission and does not require endoscopic data nor patient
observation for a prolonged period. The Birmingham Score
outperforms the GlasgowBlatchford Score, Rockall, modified
Oakland and AIM65 in predicting adverse outcomes from
LGIB. This can potentially guide early clinical decision mak-
ing including identifying patients that may require more inten-
sive treatment. Further prospective validation is required be-
fore The Birmingham Score can be utilized in routine clinical
practice.
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